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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) represent 1% of all 
gastrointestinal tract neoplasms and have an approximate in-
cidence of 10 to 20 cases per million individuals per year [1]. In 
the United States, approximately 4,500 new cases of GIST are 
diagnosed each year [1]. The average age of patients at pre-
sentation is 60 years, and there is no gender predilection [1-
3]. GISTs may arise from the stomach (50-60% of GISTs), small 
bowel (20-30%), large bowel (10%), and esophagus (5%), or 
elsewhere in the abdominal cavity (e.g., omentum, mesentery) 
(5%) [4].
GISTs were initially described in the 1940s by Stout, who 
suggested that these tumors arose from the smooth muscle 
and therefore referred to them as leiomyomas or leiomyo-
sarcomas [5]. The concept that these tumors arise from the 
smooth muscle lasted until the advent of electron microscopy 
and immunohistochemistry. In 1983, Mazur and Clark [6] 
coined the term “GIST” to describe stromal tumors that had no 
differentiation into smooth muscle or into Schwann cells. In 
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Objective: To report the clinical presentation and oncologic outcomes of a series of patients who presented with an abdominal 
or pelvic mass and were diagnosed with a gastrointestinal stromal tumor (GIST).
Methods: Data were obtained on all patients who presented with an abdominal or pelvic mass between September 2007 and 
June 2010 and who were ultimately diagnosed with a GIST. The patients’ medical records were reviewed. A literature review was 
also conducted.
Results: Six patients were identified who met the inclusion criteria. All six patients had a tumor in the intestinal tract arising 
from the small bowel. The mean tumor size was 12 cm (range, 6 to 22 cm). A complete resection was achieved in five of the six 
patients. There were no intraoperative complications; one patient had a postoperative complication. Two patients were treated 
with imatinib after surgery. The mean follow-up time was 32 months (range, 0.3 to 40 months). At the last follow-up, five of the 
six patients were without any evidence of disease. One patient died of an unrelated hepatic encephalopathy. The incidence in 
our institution is 3%.
Conclusion: GISTs are uncommon; however, they should be considered in the differential diagnosis of patients presenting with 
an abdominal or pelvic mass.
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the late1990s, several groups noted a similarity between the 
neoplastic cells of GISTs and the interstitial cells of Cajal [7-9]. 
GISTs typically express the receptor tyrosine kinase c-kit, also 
known as CD117 [4]. The prognosis of patients with a GIST is 
based on tumor size, mitotic rate, and organ of origin.
The published literature on GISTs in patients who present 
with an abdominal or pelvic mass is limited to isolated case 
reports and small case series [7-14]. The goal of this study 
was to report on a series of patients who presented with a 
presumptive diagnosis of ovarian cancer and who were ulti-
mately found to have a GIST. We describe the clinical presen-
tation, surgical management, adjuvant treatment, and overall 
outcome in these patients. In this report, we also summarize 
the published literature on GISTs presenting as ovarian cancer.
MATERIALS AND METHODS
After Institutional Review Board approval was received from 
Instituto de Cancerologia, Clinica las Americas, Medellin, Co-
lombia, data were collected on patients who presented to In-
stituto de Cancerologia with an abdominal or pelvic mass be-
tween September 2007 and June 2010. Data were abstracted 
from the patients’ existing medical records on age, presenting 
symptoms, tumor size on physical examination, findings on 
imaging studies, serum CA-125 levels, intraoperative findings, 
primary site of disease, pathologic diagnosis, mitotic rate, ad-
juvant therapy, and disease status at last follow-up.
Patients were included in this study if they met the following 
criteria: complete medical records, radiologic imaging show-
ing a pelvic or abdominopelvic mass, CA-125 levels recorded, 
and a final pathology diagnosis of a GIST. CA-125 levels were 
measured by microparticle enzymatic immunoassay, and nor-
mal values were defined as <35 U/mL. Pathologic diagnosis 
was confirmed by conventional methods and through immu-
nohistochemistry using the following markers: c-Kit (CD117), 
desmin, smooth muscle actin, CD34, and S-100 protein.
We also performed a literature review on PubMed database, 
limited to the English language, using the following terms: 
“gastrointestinal stromal tumor,” “adnexal mass,” and “inciden-
tal finding.”
RESULTS
Six patients met the inclusion criteria and are the subject of 
this report. The mean age was 59 years (range, 42 to 86 years). 
All patients were referred to the Instituto de Cancerologia with 
a presumptive diagnosis of ovarian cancer. The presentations 
of these patients were as follows: lower abdominal pain with 
duration ranging from 2 weeks to 3 months prior to consulta-
tion (4 patients), abnormal uterine bleeding with duration of 
2 weeks (1 patient), and incidental finding of an adnexal mass 
on screening examination (1 patient).
On physical examination, all six patients had a palpable firm 
abdominal mass. On pelvic examination, four patients had a 
painful palpable mass and one patient had no abnormal find-
ings; one patient did not allow pelvic examination. The mean 
size of the masses was 12 cm (range, 6 to 22 cm). On imaging 
studies, four patients had an ovarian mass visualized on both 
computed tomography and ultrasonography. The other two 
patients had a mass documented on computed tomogra-
phy only (one patient) or ultrasonography only (one patient). 
The mean serum CA-125 level for all patients was 41.2 U/mL 
(range, 1.6 to 156 U/mL) and the mean level was 20.05. Only 
one patient presented with a CA-125 level greater than 35 U/
mL (156 U/mL).
All patients underwent an exploratory laparotomy and had 
a preoperative diagnosis of ovarian malignancy. At the time 
of surgery, three patients were found to have a mass arising 
from the jejunum, and the other three patients were found 
to have a mass arising from the ileum. Two patients had inci-
dental findings not described on the preoperative computed 
tomography or ultrasonography: hepatic metastatic nodules 
in one patient and a cirrhotic liver and ascites in the other pa-
tient. All patients underwent intestinal resection with end-to-
end anastomosis. Only one patient had residual disease. This 
was the patient who was found to have hepatic metastatic 
nodules during the intraoperative assessment. There were no 
intraoperative complications. The postoperative course was 
complicated in one patient, who developed a postoperative 
ileus that resolved after 6 days of conservative management. 
The mean hospital stay for all patients was 6 days (range, 5 to 
8 days).
On final pathology review, all patients had immunohis-
tochemical analysis and all stained positive for CD117, two 
patients had disease considered to be intermediate risk for 
recurrence and four had disease considered as high risk. 
The clinical oncologist reviewed all cases. The patients with 
intermediate-risk disease did not receive adjuvant therapy 
due their low mitosis rate. Two of the patients with high-risk 
disease were treated with imatinib (400 mg daily) after sur-
gery. One of these two patients had a high rate of mitosis (28 
per 50 high-power fields [HPF]) and underwent therapy with 
imatinib for a year; the other patient had evidence of residual 
disease in the liver and is still on imatinib treatment to date. 
One of the patients with high-risk disease did not receive 
adjuvant therapy because of the low mitotic rate of the tu-Mario Muñoz, et al.
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mor. The other patient with high-risk disease died soon after 
surgery from encephalopathy associated with cirrhosis. At a 
mean follow-up time of 32 months (range, 0.3 to 40 months), 
all five patients who were still alive were without any evidence 
of disease. As there were only 6 patients, this would not allow 
for appropriate statistical analysis. A total of approximately 
200 patients with ovarian cancer were operated at Instituto de 
Cancerologia Las Americas during the time span of the study. 
Based on this information the incidence is approximately 3%. 
As a result of our literature review, we found eight reports 
including 11 patients who presented with an abdominal or 
pelvic mass and were ultimately diagnosed with a GIST. The 
details on these patients as well as the six patients in the cur-
rent series are presented in Table 1. The mean age of the 11 
previously reported patients was 53 years (range, 20 to 83 
years). Most patients presented complaining of an abdominal 
mass. The diagnostic images usually showed irregular lesions 
with areas of necrosis of heterogeneous content ranging in 
size from 5 cm to giant or even carcinomatosis. All 11 patients 
underwent surgical resection, and six (54%) of them were 
treated with the tyrosine kinase inhibitor imatinib. The mean 
reported follow-up time was 12.2 months (range, 4 to 36 
months). No patients were reported to have relapsed during 
follow-up; one patient had carcinomatosis at the time of sur-
gery, progression before starting imatinib, but stable lesions at 
6 months [8].
DISCUSSION
GISTs are rare tumors and may present a diagnostic dilem-
ma. Complete surgical resection is considered the standard 
treatment for localized tumors. Segmental intestinal resection 
is often necessary as these tumors present with an exophytic 
(bulky growth) rather than infiltrative pattern. When segmen-
tal resection is not possible, a wide, en bloc resection should 
be performed [10,15]. For metastatic and recurrent disease, 
surgery remains the first choice of therapy [1,15].
Approximately 95% of GISTs express the marker c-kit (CD117) 
[16]. Detection of receptor tyrosine kinase c-kit status is critical 
in the management of GISTs since tyrosine kinase inhibitors such 
as imatinib (Gleevec), sunitinib (Sutent), sorafenib (Nexavar), 
dasatinib, IPI504, oblimersen (Genasense), and perifosine have 
been shown to be effective treatments [4,17]. The use of such 
tyrosine kinase inhibitors is considered the standard therapy 
in patients with metastatic or unresectable disease [15,17].
The preferred imaging modality in the evaluation of patients 
with a suspected GIST is enhanced computed tomography. 
The predominant pattern is a heterogeneously enhancing 
exophytic mass. Gastric lesions are characterized by a homo-
geneous enhancement, while small bowel lesions are more 
heterogeneous. Since most GISTs grow exophytically and do 
not compromise the bowel concentrically, findings consis-
tent with intestinal obstruction are not very common even 
Table 1. Patient characteristics
Author Year Cases
Age
(yr)
Size (cm)
Mitotic rate 
(HPF)
Residual 
disease
Adjuvant 
therapy
Follow-up 
(mo)
Outcome CA-125
Powell [7] 2002 2 76
83
7×6×5
5.5×5×4.2
<1/10
None
No
No
NA
NA
12 
6 
Disease free
Disease free
8
NA
Zighelboim [8] 2003 1 31 Carcinomatosis 5-6/10 Yes Imatinib 6 Stable disease 76.1
Belics [11] 2003 1 20 19×18×7 Rare Yes NA 36 Disease free NA
Carlomagno [10] 2004 1 42 12×9.5 NA No No NA NA 61.8
Hsu [9] 2006 2 54
67
20
9
>10/50
>5/50
No
No
Imatinib
Imatinib
24
6
Disease free
Disease free
NA
NA
Pinto [12] 2007 2 42
76
4.8
17
9/50
7/50
No
No
Imatinib
Imatinib
16
12
Disease free
Disease free
NA
NA
Matteo [13] 2008 1 56 30 /15 / 7 18/50 Yes Imatinib 4 Disease free 55
Angioli [14] 2009 1 38 17 17/50 Yes NA NA NA 38.5
Muñoz
(Present series)
2010 6 42
50
79
54
46
65
6×6×4
6×4.5×3.5
27×34
12×10×7
33×32
10
<5/50
3/50
28/50
None
None
>12/50
No
No
No
No
Yes
No
No
No
Imatinib
No
Imatinib
No
40
36
34
30
18
Died
Disease free
Disease free
Disease free
Disease free
Disease control
Died
23.6
15
1.62
16.5
34.4
156
HPF, high-power fields; NA, not available.GIST presenting as ovarian neoplasms
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with very large masses. Mesenteric extension may occur with 
encasement of adjacent organs [18-21]. Distal small bowel 
tumors and those arising from the sigmoid colon and rectum 
may be erroneously identified as gynecologic cancers [22].
Gross histopathologic findings typically include a fish-flesh 
appearance of soft consistency. Tumors can be necrotic or 
present with cystic degeneration. Approximately 70% are 
composed of spindle cells, 20% of epithelioid cells, and 10% 
have a mixed phenotypic appearance [22-24]. Other markers 
expressed by these tumors are CD34 (70% of tumors), smooth 
muscle actin (30%), h-caldesmon (60%), and S-100 (5%) 
[24,25]. The DOG1 (discovered on GIST) marker is a fragment 
of cDNA encoding a protein whose function is unknown. This 
marker may be helpful when a GIST is negative for c-kit; DOG1 
has high sensitivity (94.4%) in the diagnosis of GISTs and is 
positive in 30% of those that are negative for c-kit [26,27].
The prognosis of patients with a GIST is based on tumor size 
and number of mitoses. Tumors smaller than 2 cm with fewer 
than 5 mitoses per 50 HPF are considered very low risk for re-
currence. Tumors measuring 2 to 5 cm with fewer than 5 mi-
toses per 50 HPF are considered low risk. Tumors smaller than 
5 cm with 6 to 10 mitoses per 50 HPF and tumors measuring 5 
to 10 cm with fewer than 5 mitoses per 50 HPF are considered 
intermediate risk. High-risk tumors are those measuring 5 to 
10 cm with 6 to 10 mitoses per 50 HPF, any tumor larger than 
10 cm, and any tumor with more than 10 mitoses per 50 HPF 
[2,12,28].
All patients diagnosed with a GIST that is considered inter-
mediate risk or high risk should be treated with a tyrosine 
kinase inhibitor—either imatinib 400 mg per day (first choice) 
or sunitinib 50 mg per day for 4 weeks on and 2 weeks off 
(second choice) either of them for at least 1 year. These regi-
mens have been shown to improve disease-free survival and 
overall survival [1,16,17,26,27,29]. In patients treated with ty-
rosine kinase inhibitors, studies have documented a relapse-
free survival rate of 97% at 1 year, a 5-year disease-free survival 
rate of 65%, and a 5-year disease-specific survival rate of 68% 
[4,29]. 
Unlike tyrosine kinase inhibitors, systemic chemotherapy has 
minimal effect on GISTs and thereby is not recommended for 
either neoadjuvant or adjuvant therapy [1]. Complete resec-
tion is curative in patients with low-risk tumors, even without 
lymph node resection; lymphadenectomy does not improve 
survival since lymph node metastases are rare [1,16], and there 
is no need for adjuvant therapy in both very low risk and low 
risk patients . In patients with unresectable GISTs, neoadju-
vant therapy with tyrosine kinase inhibitors can lead to a less 
extensive surgical procedure and decrease the risk of tumor 
rupture and bleeding during resection [1,17,18,29]. As cited 
by several authors, tumors arising in the small intestine have 
been shown to be more aggressive and are associated with a 
poorer prognosis and higher rate of progressive disease than 
those arising from the stomach [16,30,31].
In summary, the diagnosis of a GIST should be entertained 
in all patients diagnosed with an abdominal or pelvic mass. 
All patients with intermediate and high-risk GISTs should be 
treated postoperatively with tyrosine kinase inhibitors.
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